May 27, 2021
Article
This article features insights from Phillip Kuo, MD, PhD, and Andre Abreu, MD, on gallium 68 PSMA-targeted PET imaging in prostate cancer.
May 27, 2021
Video
Andre Abreu, MD, and Phillip Kuo, MD, PhD, on future use of PSMA targeted therapy, including insight on the phase 3 VISION trial, which used 68Ga-PSMA-11 PET/CT to identify patients for targeted treatment with 177Lu-PSMA-617.
May 27, 2021
Video
The FDA’s approval of Ga-68 PSMA-11 and its impact on ensuring accessibility of generator versus cyclotron for new radiotracers is discussed from a nuclear medicine perspective.
May 21, 2021
Video
Phillip Kuo, MD, PhD, reviews the sensitivity of PSMA (prostate-specific membrane antigen) PET (positron emission tomography) scans compared to conventional imaging.